Trial Profile
A Multicenter, Double-blind, Randomized Study Comparing the Safety and Tolerability of Iloprost Inhalation Solution Delivered by I-neb Utilizing Power Disc-15 and Power Disc-6 in Patients With Symptomatic Pulmonary Arterial Hypertension [EXTENSION OF 700242586]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2014
Price :
$35
*
At a glance
- Drugs Iloprost (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms PROWESS 15 Ext
- Sponsors Actelion Pharmaceuticals
- 29 Mar 2014 New trial record
- 30 Apr 2010
- 11 Sep 2009